Compare SCSC & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCSC | GERN |
|---|---|---|
| Founded | 1992 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 909.7M | 900.1M |
| IPO Year | 1994 | 1996 |
| Metric | SCSC | GERN |
|---|---|---|
| Price | $40.38 | $1.39 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $43.00 | $3.00 |
| AVG Volume (30 Days) | 158.6K | ★ 9.1M |
| Earning Date | 02-05-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.79 | N/A |
| EPS | ★ 3.20 | N/A |
| Revenue | ★ $3,004,880,000.00 | $183,403,000.00 |
| Revenue This Year | $5.40 | $147.42 |
| Revenue Next Year | $5.34 | $37.07 |
| P/E Ratio | $12.73 | ★ N/A |
| Revenue Growth | N/A | ★ 522.13 |
| 52 Week Low | $28.75 | $1.04 |
| 52 Week High | $51.66 | $3.12 |
| Indicator | SCSC | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 49.39 | 54.24 |
| Support Level | $39.34 | $1.26 |
| Resistance Level | $41.78 | $1.37 |
| Average True Range (ATR) | 1.08 | 0.08 |
| MACD | 0.09 | -0.00 |
| Stochastic Oscillator | 53.46 | 52.27 |
ScanSource Inc provides value-added services for technology manufacturers and sells to resellers in specialty technology markets. The firm's operations are organized in two segments: Specialty Technology Solutions and Intelisys & Advisory Segment. It generates maximum revenue from the Specialty Technology Solutions segment. The Specialty Technology Solutions segment includes the company's business in mobility and barcode, POS, payments, security and networking technologies. Geographically, it derives a majority of revenue from the United States and Canada, and also has its presence in Brazil, and other countries.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.